Papers by Rafael Fabregas
International Journal of Surgery Case Reports, 2016
Bookmarks Related papers MentionsView impact
Revista de Senología y Patología Mamaria, 2015
Bookmarks Related papers MentionsView impact
Progresos de Obstetricia y Ginecología, 2007
Bookmarks Related papers MentionsView impact
Medicina clínica, Jan 30, 2009
We evaluated the patients' selection and the results of the detection of mutations as well as... more We evaluated the patients' selection and the results of the detection of mutations as well as the follow-up of families at a genetic counselling unit. One hundred and fifty three patients were visited corresponding to 137 families: 77 of them were classified as high-risk group, 35 as moderate-risk and 25 as low-risk. The classification of patients in each group was made according to the recommendations of the guidelines and the "Oncoguia de càncer familiar" of the Departament de Salut de la Generalitat de Catalunya. With regard to familiar antecedents, patients of the high-risk group had an average (standard deviation) of 2.80 (1.5) cases of breast and/or ovarian cancer, while it was 1.82 (0.75) in the moderate-risk group, and 1.05 (0.80) in the low-risk group. Thirty seven families of high-risk (51.9%) were studied for the detection of deleterious mutations in BRCA1/2. Of 37 completed studies, 5 were positive (one BRCA1 and one BRCA2), 3 had variants of unknown signif...
Bookmarks Related papers MentionsView impact
Medicina clínica, Jan 4, 2014
Pregnancy-associated breast cancer is defined as breast cancer diagnosed during pregnancy and up ... more Pregnancy-associated breast cancer is defined as breast cancer diagnosed during pregnancy and up to one year postpartum. A retrospective, analytical, observational study comparing 56 cases of breast cancer and pregnancy (PABC) diagnosed 1976-2008 with 73 patients with breast cancer not associated with pregnancy (non-PABC) was performed. Demographic data, prognostic factors, treatment and survival were reviewed and compared. The prevalence of PABC in our center is 8.3/10,000. The highest frequency (62%) appeared during the postpartum period. The stages are higher in PABC, being 31.3% advanced (EIII and EIV) in PABC versus 13.3% in non-PABC (P < .05). Regarding prognostic factors, 27.3% in PABC had a tumoral grade 3 versus 15.8% of non-PABC. Among women with PABC, 33.3% had negative estrogen receptors, 48.7% negative progesterone receptors and 34.5% positive Her2Neu compared with 22.2, 24.1 and 31%, respectively of non-PABC patients. Finally, positive lymph nodes were found in 52.8...
Bookmarks Related papers MentionsView impact
The Breast Journal, 2007
Bookmarks Related papers MentionsView impact
Reproductive BioMedicine Online, 2014
Bookmarks Related papers MentionsView impact
Journal of Lower Genital Tract Disease, 2000
Bookmarks Related papers MentionsView impact
Gynecological Endocrinology, 2007
Research has suggested an association between the use of ovulation induction drugs and the risk o... more Research has suggested an association between the use of ovulation induction drugs and the risk of ovarian cancer. It has also been proposed that there may be pre-cancerous alterations in the ovary which themselves are the cause of infertility. The aim of the present study was to evaluate the relationship between the use of ovulation induction drugs and the appearance of borderline ovarian tumors. This was a case-control study in which the study group comprised 42 women with a borderline ovarian tumor and the control group comprised 257 women with benign ovarian pathology. No differences were found between the borderline tumor and control groups (14.3% vs. 27.2%, respectively) in terms of infertility history. Nor were there any differences between the groups with respect to the type of drug used, whether clomiphene citrate (9.5% vs. 6.2%, respectively) or gonadotropins (7.1% vs. 10.1%, respectively). Analysis in terms of the number of cycles administered also failed to reveal any differences. The mean number of cycles with clomiphene citrate/gonadotropins was 2.50 +/- 1.00 and 3.00 +/- 2.64 in the borderline tumor group and 2.44 +/- 1.75 and 3.27 +/- 2.25 in the control group. Our series produced no evidence that ovulation induction treatment predisposes women to the development of borderline ovarian tumors.
Bookmarks Related papers MentionsView impact
Current Women's Health Reviews, 2011
Bookmarks Related papers MentionsView impact
Annals of Surgical Oncology, 2013
Bookmarks Related papers MentionsView impact
Breast Cancer Research, 2007
Bookmarks Related papers MentionsView impact
Uploads
Papers by Rafael Fabregas